Cannon CP, et al. - Given that statins as first-line lipid-lowering therapy (LLT) with the addition of non-statin agents have been recommended by guidelines for treating those with atherosclerotic cardiovascular disease (ASCVD) with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels, researchers utilized an earlier reported simulation model with enhancements in order to estimate the cardiovascular (CV) risk reduction impact of treatment intensification. Using a US claims database, they developed an ASCVD cohort and baseline risk of CV events was estimated using a Cox model. According to the findings, a substantial number of CV events could be avoided due to LLT intensification in an ASCVD population. A simulation model was developed, which applied stepwise LLT intensification logic, with a target of achieving LDL-C less than 70 mg/dL at each step. In evaluating the potential gains with several types of population-level LLT interventions, this simulation-based model could be of help.